<p>Equillium（纳斯达克股票代码：EQ - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 从 “持有” 评级下调至 “卖出” 评级。</p>
<ul>
<li>REITs 将在 2026 年反弹？7 个最佳选择，随着降息临近</li>
</ul>
<p>其他几位研究分析师也最近对该公司发表了看法。Stifel Nicolaus 在周三发布的研究报告中开始覆盖 Equillium。他们对该股票设定了 “买入” 评级和 5.00 美元的目标价格。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Equillium 股票的 “卖出（d-）” 评级。一位分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，还有一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，平均目标价格为 3.00 美元。</p>
<p><strong>查看我们对 Equillium 的最新分析</strong></p>
<h2>Equillium 股票上涨 4.9%</h2>
<ul>
<li>指引而非收益推动 Equinix 股票上涨</li>
</ul>
<p>NASDAQ:EQ 的股票在周五以 1.82 美元开盘。Equillium 的 12 个月低点为 0.27 美元，12 个月高点为 2.35 美元。该公司的 50 日移动平均线为 1.45 美元，200 日移动平均线为 1.37 美元。该股票的市值为 1.1082 亿美元，市盈率为-2.94，贝塔值为 1.87。</p>
<h2>Equillium 的内部活动</h2>
<p>在其他新闻中，首席运营官 Christine Zedelmayer 在 2 月 19 日星期四出售了 185,937 股公司的股票。股票以平均价格 1.76 美元出售，总价值为 327,249.12 美元。交易完成后，首席运营官直接持有 191,444 股公司股票，价值约 336,941.44 美元。此次交易使其持股减少了 49.27%。该出售在向证券交易委员会的备案中披露，相关文件可通过此链接访问。在过去的九十天里，内部人士已出售 328,174 股公司股票，价值为 533,163 美元。当前，内部人士持有该股票的 31.60%。</p>
<h2>机构投资者对 Equillium 的看法</h2>
<ul>
<li>每个成长型投资者都应该考虑的云计算 ETF</li>
</ul>
<p>几家对冲基金最近调整了对 EQ 的持股。Janus Henderson Group PLC 在第四季度以约 9,057,000 美元的价值购买了 Equillium 的新头寸。ADAR1 Capital Management LLC 在第三季度以约 7,951,000 美元的价值购买了 Equillium 的股份。Woodline Partners LP 在第三季度以约 5,018,000 美元的价值收购了 Equillium 的新头寸。Aberdeen Group plc 在第四季度将其在 Equillium 的持股提高了 523.6%。Aberdeen Group plc 现在拥有 2,366,688 股公司股票，价值为 3,668,000 美元，此前在上个季度又购买了 1,987,162 股。最后，Vanguard Group Inc.在第三季度将其在 Equillium 的持股提高了 59.4%。Vanguard Group Inc.现在拥有 1,313,946 股公司股票，价值为 1,879,000 美元，此前在上个季度又购买了 489,855 股。机构投资者和对冲基金持有该公司 27.05% 的股票。</p>
<h2>关于 Equillium</h2>
<p>（获取免费报告）</p>
<p>Equillium, Inc（纳斯达克：EQ）是一家临床阶段的生物制药公司，专注于开发新型免疫疗法以治疗严重的自身免疫疾病和防止器官移植排斥反应。该公司的主要治疗候选药物 EQ001（itolizumab）是一种人源化单克隆抗体，通过靶向 CD6 受体来调节 T 细胞的激活。Equillium 的管线还包括其他生物候选药物，旨在解决急性移植物抗宿主病（GVHD）和狼疮性肾炎等适应症。</p>
<p>Equillium 成立于 2015 年，总部位于加利福尼亚州拉荷亚，已从 Biocon Limited 获得 itolizumab 的许可，利用该抗体在早期临床研究中的既定安全性。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Equillium 更好</li>
<li>用这 4 个简单步骤 “防止” 你的银行账户受到影响</li>
<li>重大买入警报：Mar-a-Lago/Trump/Elon</li>
<li>有史以来最大的 IPO……向普通人开放</li>
<li>银价记录很好。每月收入更好</li>
<li>阅读此文或将永远后悔</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Equillium 吗？</h2>
<p>在你考虑 Equillium 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Equillium 并不在名单上。</p>
<p>虽然 Equillium 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做空 - Direxion

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

IBBQ

<p>华尔街禅在最近的一份报告中将 Equillium（NASDAQ:EQ）的评级从 “持有” 下调至 “卖出”。该股票目前的共识评级为 “持有”，平均目标价格为 3.00 美元。其他分析师的评级各不相同，包括一项买入、一项持有和一项卖出。Equillium 的股票开盘价为 1.82 美元，12 个月的价格区间为 0.27 美元至 2.35 美元。内部人士活动包括首席运营官 Christine Zedelmayer 出售了 185,937 股。机构投资者持有该股票的 27.05%，近期有多家对冲基金进行了显著购买</p>

<p>Equillium (NASDAQ:EQ - Get Free Report) was downgraded by Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report issued on Saturday.</p>
<div class="lb-trans"><p>Equillium（纳斯达克股票代码：EQ - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 从 “持有” 评级下调至 “卖出” 评级。</p>
</div><ul>
<li>REITs Set for a 2026 Rebound? 7 Top Picks as Rate Cuts Approach</li>
</ul>
<div class="lb-trans"><ul>
<li>REITs 将在 2026 年反弹？7 个最佳选择，随着降息临近</li>
</ul>
</div><p>Several other research analysts have also recently weighed in on the company. Stifel Nicolaus assumed coverage on Equillium in a research report on Wednesday. They set a &#34;buy&#34; rating and a $5.00 price objective on the stock. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Equillium in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and an average target price of $3.00.</p>
<div class="lb-trans"><p>其他几位研究分析师也最近对该公司发表了看法。Stifel Nicolaus 在周三发布的研究报告中开始覆盖 Equillium。他们对该股票设定了 “买入” 评级和 5.00 美元的目标价格。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Equillium 股票的 “卖出（d-）” 评级。一位分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，还有一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，平均目标价格为 3.00 美元。</p>
</div><p><strong>View Our Latest Analysis on Equillium</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Equillium 的最新分析</strong></p>
</div><h2>Equillium Stock Up 4.9%</h2>
<div class="lb-trans"><h2>Equillium 股票上涨 4.9%</h2>
</div><ul>
<li>Guidance, Not Earnings, Sends Equinix Stock Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>指引而非收益推动 Equinix 股票上涨</li>
</ul>
</div><p>Shares of NASDAQ:EQ opened at $1.82 on Friday. Equillium has a 12-month low of $0.27 and a 12-month high of $2.35. The business has a 50 day moving average of $1.45 and a 200-day moving average of $1.37. The stock has a market cap of $110.82 million, a PE ratio of -2.94 and a beta of 1.87.</p>
<div class="lb-trans"><p>NASDAQ:EQ 的股票在周五以 1.82 美元开盘。Equillium 的 12 个月低点为 0.27 美元，12 个月高点为 2.35 美元。该公司的 50 日移动平均线为 1.45 美元，200 日移动平均线为 1.37 美元。该股票的市值为 1.1082 亿美元，市盈率为-2.94，贝塔值为 1.87。</p>
</div><h2>Insider Activity at Equillium</h2>
<div class="lb-trans"><h2>Equillium 的内部活动</h2>
</div><p>In other news, COO Christine Zedelmayer sold 185,937 shares of the business's stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $1.76, for a total value of $327,249.12. Following the completion of the transaction, the chief operating officer directly owned 191,444 shares in the company, valued at approximately $336,941.44. The trade was a 49.27% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 328,174 shares of company stock valued at $533,163. 31.60% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席运营官 Christine Zedelmayer 在 2 月 19 日星期四出售了 185,937 股公司的股票。股票以平均价格 1.76 美元出售，总价值为 327,249.12 美元。交易完成后，首席运营官直接持有 191,444 股公司股票，价值约 336,941.44 美元。此次交易使其持股减少了 49.27%。该出售在向证券交易委员会的备案中披露，相关文件可通过此链接访问。在过去的九十天里，内部人士已出售 328,174 股公司股票，价值为 533,163 美元。当前，内部人士持有该股票的 31.60%。</p>
</div><h2>Institutional Investors Weigh In On Equillium</h2>
<div class="lb-trans"><h2>机构投资者对 Equillium 的看法</h2>
</div><ul>
<li>The Cloud Computing ETF Every Growth Investor Should Consider</li>
</ul>
<div class="lb-trans"><ul>
<li>每个成长型投资者都应该考虑的云计算 ETF</li>
</ul>
</div><p>Several hedge funds have recently modified their holdings of EQ. Janus Henderson Group PLC bought a new position in Equillium in the fourth quarter valued at about $9,057,000. ADAR1 Capital Management LLC bought a new stake in shares of Equillium during the third quarter worth about $7,951,000. Woodline Partners LP acquired a new position in shares of Equillium in the third quarter valued at approximately $5,018,000. Aberdeen Group plc raised its holdings in Equillium by 523.6% in the 4th quarter. Aberdeen Group plc now owns 2,366,688 shares of the company's stock valued at $3,668,000 after buying an additional 1,987,162 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Equillium by 59.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company's stock valued at $1,879,000 after buying an additional 489,855 shares during the last quarter. Institutional investors and hedge funds own 27.05% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对 EQ 的持股。Janus Henderson Group PLC 在第四季度以约 9,057,000 美元的价值购买了 Equillium 的新头寸。ADAR1 Capital Management LLC 在第三季度以约 7,951,000 美元的价值购买了 Equillium 的股份。Woodline Partners LP 在第三季度以约 5,018,000 美元的价值收购了 Equillium 的新头寸。Aberdeen Group plc 在第四季度将其在 Equillium 的持股提高了 523.6%。Aberdeen Group plc 现在拥有 2,366,688 股公司股票，价值为 3,668,000 美元，此前在上个季度又购买了 1,987,162 股。最后，Vanguard Group Inc.在第三季度将其在 Equillium 的持股提高了 59.4%。Vanguard Group Inc.现在拥有 1,313,946 股公司股票，价值为 1,879,000 美元，此前在上个季度又购买了 489,855 股。机构投资者和对冲基金持有该公司 27.05% 的股票。</p>
</div><h2>About Equillium</h2>
<div class="lb-trans"><h2>关于 Equillium</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Equillium, Inc NASDAQ: EQ is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.</p>
<div class="lb-trans"><p>Equillium, Inc（纳斯达克：EQ）是一家临床阶段的生物制药公司，专注于开发新型免疫疗法以治疗严重的自身免疫疾病和防止器官移植排斥反应。该公司的主要治疗候选药物 EQ001（itolizumab）是一种人源化单克隆抗体，通过靶向 CD6 受体来调节 T 细胞的激活。Equillium 的管线还包括其他生物候选药物，旨在解决急性移植物抗宿主病（GVHD）和狼疮性肾炎等适应症。</p>
</div><p>Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.</p>
<div class="lb-trans"><p>Equillium 成立于 2015 年，总部位于加利福尼亚州拉荷亚，已从 Biocon Limited 获得 itolizumab 的许可，利用该抗体在早期临床研究中的既定安全性。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Equillium</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>MAJOR BUY ALERT: Mar-a-Lago/Trump/Elon</li>
<li>The Biggest IPO Ever… Open to Everyday Folks</li>
<li>Silver records prices are great. Monthly income is better</li>
<li>Read this or regret it forever</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Equillium 更好</li>
<li>用这 4 个简单步骤 “防止” 你的银行账户受到影响</li>
<li>重大买入警报：Mar-a-Lago/Trump/Elon</li>
<li>有史以来最大的 IPO……向普通人开放</li>
<li>银价记录很好。每月收入更好</li>
<li>阅读此文或将永远后悔</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Equillium Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Equillium 吗？</h2>
</div><p>Before you consider Equillium, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Equillium 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Equillium wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Equillium 并不在名单上。</p>
</div><p>While Equillium currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Equillium 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Equillium（NASDAQ:EQ）被华尔街 Zen 下调评级至 “卖出”